about
Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease.Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome.Vitamins and Microelement Bioavailability in Different Stages of Chronic Kidney Disease.Water soluble vitamins and peritoneal dialysis - State of the art.Dietary Intake of Vitamins in Different Options of Treatment in Chronic Kidney Disease: Is There a Deficiency?Inflammation and Protein-Energy Wasting in the Uremic Milieu.CD28 positive, cytomegalovirus specific cytotoxic T lymphocytes as a novel biomarker associated with cytomegalovirus viremia in kidney allorecipients.Skin cancer in kidney transplant recipients affected with autosomal dominant polycystic kidney disease.Sclerostin─A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?Kidney transplantation does not increase the level of basic hope or life satisfaction compared with hemodialysis in patients with chronic kidney disease.Impact of donor and recipient human cytomegalovirus status on kidney transplantation.Biologically active form of vitamin B1 in human peritoneal effluent.Thiamine Diphosphate Status and Dialysis-Related Losses in End-Stage Kidney Disease Patients Treated with Hemodialysis.Vitamin B6 and the immunity in kidney transplant recipients.The modification of diet in renal disease and chronic kidney disease epidemiology collaboration formulas versus measured or estimated creatinine clearance in kidney transplant recipients.Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?Tissue Doppler Imaging and Intima-Media Thickness as Noninvasive Methods of Cardiovascular Risk Stratification in Patients After Kidney Transplantation.Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4+ T-cells.HLA-B27 is a potential risk factor for posttransplantation diabetes mellitus in autosomal dominant polycystic kidney disease patients.Autosomal Dominant Polycystic Kidney Disease Is Not a Risk Factor for Post-transplant Diabetes Mellitus. Matched-pair Design Multicenter StudyObesity Risk Factors in Patients After Kidney TransplantationEpidemiology of Posttransplantation Chronic Kidney Disease Can Be Altered by Choice of Formula Estimating Glomerular Filtration RateVitamin B6 Status, Immune Response and Inflammation Markers in Kidney Transplant Recipients Treated With Polyclonal Anti-thymocyte GlobulinEffects of Renal-specific Oral Supplementation in Malnourished Hemodialysis PatientsA Single-Center Experience of Renal Transplantation in Elderly Patients: A Paired-Kidney AnalysisBioelectrical Impedance Analysis Before Versus After a Hemodialysis Session in Evaluation of Nutritional StatusNative Nephrectomy in Renal Transplant Recipients With Autosomal Dominant Polycystic Kidney DiseaseMRI-derived markers for predicting a decline in renal function in patients with autosomal dominant polycystic kidney diseaseA distinct bone phenotype in ADPKD patients with end-stage renal diseaseAmino acid profile after oral nutritional supplementation in hemodialysis patients with protein-energy wasting
P50
Q36145849-05D6F064-8709-4852-8E39-E1D5A38AF756Q36707314-B2F0EB97-ECBA-473B-BDF9-49770441ACA3Q37729838-6B11229C-5750-4C63-A9B2-F04C3BABCC06Q39019600-A4001F27-F407-4DDE-BD70-8E89B564E439Q39518584-5FEC0850-A57F-413C-8B24-BEC02CB8E1C9Q40045981-9A331A59-70B6-417A-9383-4C107C046D7DQ40575410-0BC1E0C9-DD40-482B-BCF6-D116781F16D8Q42489550-9923464C-48AC-4744-B3EE-CA6E5027F07DQ44683026-34F2EB28-36C3-4C01-90BB-634BAB8966FDQ45328407-1F882552-8F10-4904-9B34-AF4AAB2B7C22Q47585004-674C7FCC-D7C5-4924-A540-0F6F8114D8A4Q50015555-3EC5955A-8090-4883-96F7-6084C83A46F3Q50101653-98C2D60C-41B9-45D9-B557-6351AD44FF48Q50955625-3D3A8415-160A-4D25-869E-6E1C55480219Q51014724-1D0191A8-7FD7-4D5C-8559-03A1F0E1897EQ51479672-8D98533E-65D9-4E4D-B7BE-96CD3F143CAFQ52978297-6F6955F8-F89F-486A-AABD-8889098096D1Q53349501-CC3D8B29-992C-4C3B-8A25-EA0D1E747D95Q54400848-7661CDED-2309-4BD4-97EF-CF9ED18034BBQ61945643-E9C5FF54-E520-405D-89E3-1DC2BEEB6947Q62588944-7C800728-D2AF-41DF-8EE6-08FCB6C77561Q62588946-F76E6FCB-3B93-4051-96CC-8C4FAB951523Q62588948-A754C9BC-4FAD-4746-81A2-0033B5799CB7Q62588950-7E6D2A07-93F9-442B-9014-E9A6E120B18FQ62588951-DEA67A54-5EB0-455D-A636-69EF7FC2E0D0Q62588953-9BB7E3E6-7AC9-42A0-B054-3A24080B9781Q90595719-FDC9C814-5563-46DA-8391-B9A6EFC8535EQ90861581-1BF8BC53-938B-43BD-A283-2FCCFFAEA2ADQ91146509-775BD2AA-2A2B-4FD9-8A77-941AAAB85687Q91299441-F3EDB8DD-B50A-413F-98EC-A4BC2B0F00A7
P50
description
Forscher
@de
chercheur
@fr
hulumtuese
@sq
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Magdalena Jankowska
@ast
Magdalena Jankowska
@en
Magdalena Jankowska
@es
Magdalena Jankowska
@nl
type
label
Magdalena Jankowska
@ast
Magdalena Jankowska
@en
Magdalena Jankowska
@es
Magdalena Jankowska
@nl
prefLabel
Magdalena Jankowska
@ast
Magdalena Jankowska
@en
Magdalena Jankowska
@es
Magdalena Jankowska
@nl
P214
P1153
35302394200
P21
P214
P31
P496
0000-0002-2432-6350
P734
P735
P7859
viaf-313522649